+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Type 1 Diabetes Drug Market by Form (Insulin Therapy, Oral Medication), End User (Drugstore, Hospital) - Forecast 2024-2030- Product Image
Global Type 1 Diabetes Drug Market by Form (Insulin Therapy, Oral Medication), End User (Drugstore, Hospital) - Forecast 2024-2030- Product Image
Sale

Global Type 1 Diabetes Drug Market by Form (Insulin Therapy, Oral Medication), End User (Drugstore, Hospital) - Forecast 2024-2030

  • PDF Icon

    Report

  • 194 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4985893
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Type 1 Diabetes Drug Market size was estimated at USD 17.57 billion in 2023, USD 19.14 billion in 2024, and is expected to grow at a CAGR of 9.06% to reach USD 32.24 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Type 1 Diabetes Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Type 1 Diabetes Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Type 1 Diabetes Drug Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, B. Braun Melsungen AG, Biocon Limited, DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XOMA Corporation.

Market Segmentation & Coverage

This research report categorizes the Type 1 Diabetes Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Form
    • Insulin Therapy
      • Long-Acting Insulin
      • Premix Analogs
      • Rapid Acting Insulin
    • Oral Medication
      • Biguanides
        • Metformine
        • Metformine Extended-Release
      • Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
        • Canaglifozine
        • Dapagliflozine
        • Empagliflozine
        • Ertugliflozine
  • End User
    • Drugstore
    • Hospital
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Type 1 Diabetes Drug Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Type 1 Diabetes Drug Market?
  3. What are the technology trends and regulatory frameworks in the Type 1 Diabetes Drug Market?
  4. What is the market share of the leading vendors in the Type 1 Diabetes Drug Market?
  5. Which modes and strategic moves are suitable for entering the Type 1 Diabetes Drug Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Type 1 Diabetes Drug Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of type 1 diabetes globally
5.1.1.2. Increasing healthcare expenditure with rising disposable income
5.1.1.3. Rising patient awareness on type 1 diabetes treatment
5.1.2. Restraints
5.1.2.1. Patent expiration of drugs
5.1.3. Opportunities
5.1.3.1. Emerging introduction of novel drugs to treat diabetes
5.1.3.2. Surge in research and development activities for type 1 anti-diabetic drugs
5.1.4. Challenges
5.1.4.1. Strict regulations for the approval drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Type 1 Diabetes Drug Market, by Form
6.1. Introduction
6.2. Insulin Therapy
6.3.1. Long-Acting Insulin
6.3.2. Premix Analogs
6.3.3. Rapid Acting Insulin
6.3. Oral Medication
6.4.1. Biguanides
6.4.2.1. Metformine
6.4.2.2. Metformine Extended-Release
6.4.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
6.4.3.1. Canaglifozine
6.4.3.2. Dapagliflozine
6.4.3.3. Empagliflozine
6.4.3.4. Ertugliflozine
7. Type 1 Diabetes Drug Market, by End User
7.1. Introduction
7.2. Drugstore
7.3. Hospital
8. Americas Type 1 Diabetes Drug Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Type 1 Diabetes Drug Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Type 1 Diabetes Drug Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Astellas Pharma Inc.
12.1.2. AstraZeneca PLC
12.1.3. B. Braun Melsungen AG
12.1.4. Biocon Limited
12.1.5. DAIICHI SANKYO COMPANY, LIMITED
12.1.6. Eli Lilly and Company
12.1.7. GSK plc
12.1.8. Johnson & Johnson Services, Inc.
12.1.9. Novartis AG
12.1.10. Novo Nordisk A/S
12.1.11. Pfizer Inc.
12.1.12. Samsung Bioepis Co., Ltd.
12.1.13. Sanofi S.A.
12.1.14. Teva Pharmaceutical Industries Ltd.
12.1.15. XOMA Corporation
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. TYPE 1 DIABETES DRUG MARKET RESEARCH PROCESS
FIGURE 2. TYPE 1 DIABETES DRUG MARKET SIZE, 2022 VS 2030
FIGURE 3. TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. TYPE 1 DIABETES DRUG MARKET DYNAMICS
FIGURE 7. TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2022 VS 2030 (%)
FIGURE 8. TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 10. TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 12. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 14. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 20. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 6. TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 8. TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 13. TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 15. TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 19. TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 24. TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 46. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 47. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 48. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 49. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 50. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 52. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 53. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 55. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 78. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 79. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 80. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 81. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 84. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 85. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 86. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 87. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 96. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 97. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 98. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 99. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 108. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 114. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 115. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 120. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 121. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 126. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 127. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 132. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 133. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 134. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 135. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 138. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 150. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 151. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 152. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 153. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 154. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 157. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 158. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 159. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 160. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 163. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 164. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 165. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 166. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 169. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 170. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 171. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 172. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 175. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 176. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 177. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 178. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 187. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 188. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 189. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 190. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 199. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 205. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 206. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 207. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 208. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 211. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 212. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 213. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 214. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 217. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 218. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 219. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 220. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 241. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 242. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 243. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 244. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 259. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 260. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 261. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 262. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 277. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2022
TABLE 278. TYPE 1 DIABETES DRUG MARKET LICENSE & PRICING

Companies Mentioned

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • B. Braun Melsungen AG
  • Biocon Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • XOMA Corporation

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 19.14 Billion
Forecasted Market Value ( USD ) by 2030 $ 32.24 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global Non-insulin Diabetes Therapeutics Market 2023-2027 - Product Image

Global Non-insulin Diabetes Therapeutics Market 2023-2027

  • Report
  • 172 Pages
  • Global
From
Global Human Insulin Drugs Market by Insulin Type (Basal or Long-Acting Insulins, Biosimilar Insulins, Intermediate-Acting Insulin), Delivery Devices (Insulin Pens, Insulin Pumps, Insulin Syringes), Application, Distribution Channel - Forecast 2024-2030 - Product Image

Global Human Insulin Drugs Market by Insulin Type (Basal or Long-Acting Insulins, Biosimilar Insulins, Intermediate-Acting Insulin), Delivery Devices (Insulin Pens, Insulin Pumps, Insulin Syringes), Application, Distribution Channel - Forecast 2024-2030

  • Report
  • 192 Pages
  • Global
From
Basal Insulin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Basal Insulin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 100 Pages
  • Global
From
Global Insulin Market by Drug (Biologic, Biosimilar), Type (Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin), Application - Forecast 2023-2030 - Product Image

Global Insulin Market by Drug (Biologic, Biosimilar), Type (Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin), Application - Forecast 2023-2030

  • Report
  • 196 Pages
  • Global
From
Human Insulin Drugs and Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029 - Product Image

Human Insulin Drugs and Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

  • Report
  • 120 Pages
  • Global
From

About the Market

The Type 1 Diabetes Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat Type 1 Diabetes, an autoimmune disorder in which the body's immune system attacks the cells that produce insulin. These drugs are used to help regulate blood sugar levels and reduce the risk of complications associated with the disease. Commonly used Type 1 Diabetes Drugs include insulin, sulfonylureas, meglitinides, and GLP-1 agonists. These drugs are typically administered orally or through injection. The Type 1 Diabetes Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.